Drug intelligence / Profile preview

prednisone + terbinafine

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules
Administration: Oral, Topical

Overview

A combination of prednisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and terbinafine (an allylamine antifungal that inhibits squalene epoxidase). This combination is used for treating certain fungal infections where inflammation is also present, though caution is advised as corticosteroids may potentially worsen fungal infections.

Targets

GR (Glucocorticoid receptor)SQLE (Squalene monooxygenase)

Beyond the preview

Go deeper on prednisone + terbinafine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on prednisone + terbinafine.

Explore the full profile